AMRI becomes approved manufacturer of lipid excipients for Pfizer-BioNTech vaccine

March 1, 2021

Joins network of manufacturers contributing efforts to increase supply

Albany Molecular Research, Inc. (AMRI), a contract research development and manufacturing organization, has been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech Covid-19 vaccine.

For the past few months, AMRI has been providing development, scale-up and manufacturing services at a number of its global R&D and production sites, offering operational flexibility and expertise to deliver capacity for lipid excipient supply for the vaccine at speeds necessary to support the program. This lipid excipient surrounds and protects the vaccine’s active ingredient.

“We are proud to support Pfizer and BioNTech in this global effort to halt the spread of Covid-19 and prevent further occurrence of this devastating disease,” said John Ratliff, AMRI’s CEO. “We are committed to playing a vital role in ending this pandemic, from our work in support of antivirals and vaccines, to the continued production of essential medicines used for Covid-19 patients.”